1316 Initial monotherapy clinical activity of invikafusp alfa, a first-in-class TCR β-chain-targeted bifunctional antibody, in tissue-agnostic, TMB-H patients from STARt-001, a phase 1/2 trial
Bibliographic record
Abstract
Background Invikafusp alfa (STAR0602), a selective, dual T cell agonist targeting Vβ6/10 TCRs, is being evaluated as monotherapy in the Phase 2 expansion of START-001, a multicenter Phase 1/2 trial in patients with tissue-agnostic TMB-H (≥ 10 mut/Mb) and/or microsatellite instability (MSI)-H solid tumors.Methods Ongoing Phase 2 expansion enrolls patients with TMB-H/MSI-H solid tumors to 3 separate cohorts: tissue-agnostic TMB-H or MSI-H, and colorectal cancer. All patients receive recommended Phase 2 dose of 0.08 mg/kg i.v. invikafusp, Q2W. Here we report the first pooled results ever presented for tissue-agnostic, TMB-H patients from Phase 2 and Phase 1 who received optimal biological dose (range 0.08 to 0.12 mg/kg).Results As of 30 June 2025, 47 patients across 17 different TMB-H solid tumors were enrolled: 33% received ≥ 4 lines of prior therapy; 70% received prior immune checkpoint blockade (ICB) and 30% were ICB-naïve because ICB were either not standard of care or not approved for the condition.Of 47 patients, 33 had ≥ 1 post treatment tumor assessment. Overall, invikafusp showed tissue-agnostic, anti-tumor activity (partial response [PR] and tumor regression) in 10 different TMB-H tumor types (table 1). Specifically, 16 patients (49%) had target lesion reduction with 8 (24%) PR and 19 (58%) stable disease (82% disease control) per RECIST. PR and tumor regression were seen in both ICB-resistant (primary and secondary) and ICB-naive patients, suggesting invikafusp’s tissue-agnostic anti-tumor activity is independent of prior ICB treatment.Invikafusp’s overall safety profile was consistent with its mechanism of action (MoA) of selective, dual T cell activation via both TCR and IL-2 co-stimulation. The most common TEAEs were low-grade, well managed with supportive care.Nanostring on 20 paired blood and tumor specimens showed: 1) unequivocal expansion of Vb6/10 T cells post treatment across all tumor types tested, confirming invikafusp’s MoA of selective expansion of in vivo tumor-infiltrating lymphocytes (TILs); 2) significant upregulation of pathways of cytotoxicity, TCR and chemokine signaling, and costimulatory molecules in TILs post treatment; and 3) downregulation of gene expressions of immune suppression (e.g., PD-1 and FOXP3) in TILs of patients with tumor reduction.Conclusions As a first-in-class, dual T cell agonist, invikasfusp showed clinically meaningful anti-tumor activity in TMB-H patients with potential to overcome ICB resistance, offering them a new class of immune-oncology therapeutics. FDA has granted a Fast Track Designation for invikafusp in TMB-H CRC. Phase 2 expansion is ongoing to further investigate the efficacy of invikafusp.Trial Registration NCT05592626Ethics Approval STARt-001 obtained ethics approval, including the following names of the ethics committee(s) or institutional review board(s), the number/ID of the approval(s). In addition,participants gave informed consent before taking part. The list of the names of the ethics committee(s) or institutional review board(s): Comite de Protection des Personnes Sud-Est III (CT # 2023-505334-10-01) CEIm HM Hospitales (CT # 2023-505334-10-01) Dana Farber Cancer Institute IRB (22-577) Comite de Protection des Personnes Sud-Est III (CT # 2023-505334-10-01) Institutional Review Board/Privacy Board/Memorial Sloan Kettering Cancer Center (23-239) CEIm HM Hospitales (CT # 2023-505334-10-01) WCG IRB (Inst Tracking #: NCT05592626) University of Miami Human Subject Research Office (HSRO) (IBIS# 20231136) NIH Office of IRB Operations (23-5345) AdventHealth Orlando IRB (2052490-3) WCG IRB (Inst Tracking #: STUDY00019146) WCG IRB (Inst. Tracking #: 24-11-7340)Abstract 1316 Table 1Invikafusp showed tissue-agnostic anti-tumor activity (partial responses and tumor regression) in 10 different tumor types with high tumor mutational burden (TMB-H*)*TMB-H defined as ≥ 10 mut/Mb per local testing #n = number of patients
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.005 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".